2024
The Road to Reintegration: Evaluating the Effectiveness of VA Healthcare in Vocational Rehabilitation and Employment Retention for Veterans with Mental Health and Substance Use Disorders
Sprong M, Hollender H, Blankenberger B, Rumrill S, Lee Y, Bland T, Bailey J, Weber K, Gilbert J, Kriz K, Buono F. The Road to Reintegration: Evaluating the Effectiveness of VA Healthcare in Vocational Rehabilitation and Employment Retention for Veterans with Mental Health and Substance Use Disorders. Substance Abuse And Rehabilitation 2024, 15: 107-123. PMID: 39081876, PMCID: PMC11287469, DOI: 10.2147/sar.s462882.Peer-Reviewed Original ResearchMental health treatmentSubstance use disorder treatmentVeterans Integrated Service NetworkVocational rehabilitation servicesVocational rehabilitation programVocational rehabilitationSubstance use disordersMental healthHealth treatmentProgram enrollmentRehabilitation servicesRehabilitation programVA healthcareVA healthcare systemSubstance use disorder treatment servicesProgram evaluation dataFace significant barriersProgram evaluation designMultivariate logistic regression analysisHealth outcomesLogistic regression analysisIntegrated services networksVeteran patientsHealthcare systemPost-dischargeVirtual Reality in Medical Education
Buono F, Marks A, Lee D. Virtual Reality in Medical Education. Cyberpsychology Behavior And Social Networking 2024, 27: 361-362. PMID: 38841871, DOI: 10.1089/cyber.2024.27599.geditorial.Peer-Reviewed Original ResearchAntipsychotic agents in anxiety disorders: An umbrella review
Garakani A, Buono F, Salehi M, Funaro M, Klimowicz A, Sharma H, Faria C, Larkin K, Freire R. Antipsychotic agents in anxiety disorders: An umbrella review. Acta Psychiatrica Scandinavica 2024, 149: 295-312. PMID: 38382649, DOI: 10.1111/acps.13669.Peer-Reviewed Original ResearchSecond-generation antipsychoticsFirst-generation antipsychoticsGeneralized anxiety disorderStudies of antipsychoticsAnxiety disordersAntipsychotic agentsEfficacy of first-generation antipsychoticsTreatment of anxiety disordersEfficacy of antipsychotic agentsMeta-analysesAntidepressant treatmentNonantipsychotic medicationsAntipsychoticsFirst-line treatmentAnxietyComparing monotherapyUmbrella reviewDisordersQuetiapineSystematic reviewSide effectsAMSTAR-2Off-labelAPA PsycInfoCINAHL CompleteUnderstanding chronic pain in Neurofibromatosis Type 1 using the Neurofibromatosis Pain Module (NFPM)
Buono F, Larkin K, Zempsky W, Grau L, Martin S. Understanding chronic pain in Neurofibromatosis Type 1 using the Neurofibromatosis Pain Module (NFPM). American Journal Of Medical Genetics Part A 2024, 194: e63541. PMID: 38234177, DOI: 10.1002/ajmg.a.63541.Peer-Reviewed Original ResearchNeurofibromatosis type 1Chronic painImpact of CPPain modulationPain regionsModerate pain severityType 1Autosomal dominant genetic disorderCross-sectional studyQuality of lifeDominant genetic disorderMedical providersPain severitySensitive clinical measureDaily functioningClinical measuresPainEffective treatmentGenetic disordersNeurofibromatosisClinical assessmentMultiple domainsAdultsQuantitative responseProviders
2023
Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials
Merker V, Thompson H, Wolters P, Buono F, Hingtgen C, Rosser T, Barton B, Barnett C, Smith T, Haberkamp D, McManus M, Baldwin A, Moss I, Röhl C, Martin S. Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials. Clinical Trials 2023, 21: 6-17. PMID: 38140900, PMCID: PMC10922038, DOI: 10.1177/17407745231205577.Peer-Reviewed Original ResearchPatient-reported outcome measuresClinical trialsOutcome measuresNeurofibromatosis 1Cutaneous neurofibromasDistress ScaleOlder adultsFinal consensus recommendationsKey secondary outcomesPatient-reported outcomesPatient-reported changesAppearance concernsSystematic literature searchNontumor manifestationsTreatment sequelaeSecondary outcomesBACKGROUND/Consensus recommendationsPatient's perspectiveTumor volumePatient representativesGood psychometric propertiesOutcome ratingsLiterature searchPlexiformWork readiness and barriers to employment during COVID-19 for individuals with Neurofibromatosis Type 1 (NF1)
Buono F, Polonsky M, Marks A, Larkin K, Sprong M. Work readiness and barriers to employment during COVID-19 for individuals with Neurofibromatosis Type 1 (NF1). Work 2023, 76: 1265-1273. PMID: 37355921, DOI: 10.3233/wor-220259.Peer-Reviewed Original ResearchFeasibility of a remotely monitored blood alcohol concentration device to facilitate treatment motivation
Buono F, Polonsky M, Sprong M, Aviles A, Cutter C. Feasibility of a remotely monitored blood alcohol concentration device to facilitate treatment motivation. Drug And Alcohol Dependence Reports 2023, 9: 100202. PMID: 38045492, PMCID: PMC10690544, DOI: 10.1016/j.dadr.2023.100202.Peer-Reviewed Original ResearchDisparities in program enrollment and employment outcomes for veterans with psychiatric and co-occurring substance use disorders referred or enrolled for VHA vocational rehabilitation
Sprong M, Hollender H, Lee Y, Williams L, Sneed Z, Garakani A, Buono F. Disparities in program enrollment and employment outcomes for veterans with psychiatric and co-occurring substance use disorders referred or enrolled for VHA vocational rehabilitation. Frontiers In Psychiatry 2023, 14: 1200450. PMID: 37520235, PMCID: PMC10382058, DOI: 10.3389/fpsyt.2023.1200450.Peer-Reviewed Original ResearchActive alcohol use disorderSubstance use disordersUse disordersVeterans Health Administration medical centersCo-occurring substance use disordersVocational rehabilitationProgram enrollmentCo-occurring alcoholCo-occurring depressionDiagnosis of anxietyCo-occurring diagnosesAlcohol use disorderPost-traumatic stress disorderInstitutional review boardVeteran patientsMedical CenterPsychiatric diagnosisCurrent studyBipolar disorderRehabilitation servicesReview boardStress disorderEffective interventionsAnxiety diagnosesDiagnosisMaintaining Engagement in Adults with Neurofibromatosis Type 1 to Use the iCanCope Mobile Application (iCanCope-NF)
Buono F, Larkin K, Pham Q, De Sousa D, Zempsky W, Lalloo C, Stinson J. Maintaining Engagement in Adults with Neurofibromatosis Type 1 to Use the iCanCope Mobile Application (iCanCope-NF). Cancers 2023, 15: 3213. PMID: 37370823, PMCID: PMC10296339, DOI: 10.3390/cancers15123213.Peer-Reviewed Original ResearchPsychosocial treatmentsContingency managementSemi-structured interviewsChronic painGoal settingEngagement dataParticipants' experiencesCurrent studyNeurofibromatosis type 1EngagementCustomized mobile applicationConsistent issueAdultsMixed methodologyPositive feedbackMixed methodsExperienceMoodPhysical activityMobile applicationsGoalPain treatmentSleepSubset of dataIndividualsImpact of Substance Use Disorders on Employment for Veterans
Sprong ME, Hollender H, Paul E, Gilbert J, Weber K, Garakani A, Buono FD. Impact of Substance Use Disorders on Employment for Veterans. Psychological Services 2023, 20: 222-231. PMID: 35849362, DOI: 10.1037/ser0000690.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersImpact of SUDMental health conditionsSerious mental health conditionsVocational rehabilitation programCommunity-based employmentMedical conditionsRehabilitation programAlcohol useHealth conditionsVeteransIllicit drugsVR programClosure statusDisordersPresent studyFindingsTransitional work
2022
Interventions Addressing Cannabis Use During Pregnancy: A Systematic Review
Groff D, Bollampally P, Buono F, Knehans A, Spotts H, Bone C. Interventions Addressing Cannabis Use During Pregnancy: A Systematic Review. Journal Of Addiction Medicine 2022, 17: 47-53. PMID: 36731108, DOI: 10.1097/adm.0000000000001027.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyCannabis useSystematic reviewMotivational interviewingBehavioral therapyMultiple adverse health outcomesAdverse health outcomesHigh-quality studiesPrevalence of cannabisStudies of interventionsMotivational enhancement therapyWeb of SciencePregnant womenCochrane LibraryObservational studyPregnancyBrief counselingHome interventionHealth outcomesPregnant peopleComputer-based interventionsEnhancement therapyPilot studySystematic searchTherapyPerspectives on adapting a mobile application for pain self-management in neurofibromatosis type 1: results of online focus group discussions with individuals living with neurofibromatosis type 1 and pain management experts
Grau LE, Larkin K, Lalloo C, Stinson JN, Zempsky WT, Ball SA, Buono FD. Perspectives on adapting a mobile application for pain self-management in neurofibromatosis type 1: results of online focus group discussions with individuals living with neurofibromatosis type 1 and pain management experts. BMJ Open 2022, 12: e056692. PMID: 35840301, PMCID: PMC9295671, DOI: 10.1136/bmjopen-2021-056692.Peer-Reviewed Original ResearchConceptsPain management expertsNeurofibromatosis type 1Type 1Self-management mobile appAudio-recorded focus groupsChronic painAPP levelsFocus groupsPainPotential associationMobile health applicationsNF1 groupTypes of participantsGenetic disordersNeeds of individualsOnline focus group discussionsOnline focus groupsFocus group discussionsAppropriate visualsGroupParticipant groupsFree accessSpecific needsIndividualsHealth applicationsThe Impact of SARS-CoV-2 (COVID-19) on the Acuity of Mental Health–Related Diagnosis at Admission for Young Adults in New York City and Washington, DC: Observational Study
Fialk A, Connors A, Cerrito B, Jones K, Buono F. The Impact of SARS-CoV-2 (COVID-19) on the Acuity of Mental Health–Related Diagnosis at Admission for Young Adults in New York City and Washington, DC: Observational Study. JMIR Formative Research 2022, 6: e39217. PMID: 35767688, PMCID: PMC9285669, DOI: 10.2196/39217.Peer-Reviewed Original ResearchMental health servicesYoung adultsMental healthObservational studyHealth servicesCOVID-19 pandemicGeneralized anxietyTreatment success rateCOVID-19SARS-CoV-2Significant differencesTreatment of individualsClinical recommendationsAdmission assessmentGroup 1Functional assessmentEqual groupsTherapy assessmentIndividual mental healthPsychometric scoresDepressionSuccess rateAdultsAdmissionQualtrics linkAn umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol
Garakani A, Freire RC, Buono FD, Thom RP, Larkin K, Funaro MC, Salehi M, Perez-Rodriguez MM. An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol. PLOS ONE 2022, 17: e0269772. PMID: 35709149, PMCID: PMC9202921, DOI: 10.1371/journal.pone.0269772.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSelective serotonin reuptake inhibitorsSerotonin-norepinephrine reuptake inhibitorsUse of antipsychoticsLong-term riskAnxiety disordersReuptake inhibitorsUmbrella reviewSide effectsPanic disorderSystematic reviewNon-antipsychotic medicationsUse of quetiapineFirst-line treatmentSerotonin reuptake inhibitorsNorepinephrine reuptake inhibitorsEvidence of efficacyCommon psychiatric disordersTraditional pharmacologic treatmentTreatment of anxietyAdjunctive treatmentPharmacologic treatmentTricyclic antidepressantsAntipsychoticsPsychiatric disordersSocial anxiety disorderThe Spanish Version of the Video Game Functional Assessment-Revised
Sprong ME, Chamarro A, Polonsky M, Pechek AA, Pilcher C, Griffiths MD, Buono FD. The Spanish Version of the Video Game Functional Assessment-Revised. Cyberpsychology Behavior And Social Networking 2022, 25: 458-464. PMID: 35594309, DOI: 10.1089/cyber.2021.0325.Peer-Reviewed Original ResearchConceptsEscape/avoidanceFunctional assessmentEvidence-based behavioral interventionsNine-item Internet Gaming Disorder ScaleInternet Gaming Disorder ScaleSpanish versionAdults 18 yearsConfirmatory factor analysisIGDS9-SFSocial attentionProblematic gamersFunction scoresHigh prevalenceBehavioral interventionsPain functionDisorder ScaleConcurrent validitySensory stimulationDistinct factorsConstruct validityCorrelational coefficientsIntangible rewardsFactor analysisGamersShort formDevelopment and validation of a new scale to measure chronic suicidal ideation: The Chronic Suicidal Ideation Inventory-5 (CSI-5)
Garakani A, Buono FD, Larkin K, Polonsky M, Goldberg JF. Development and validation of a new scale to measure chronic suicidal ideation: The Chronic Suicidal Ideation Inventory-5 (CSI-5). Journal Of Psychiatric Research 2022, 150: 160-164. PMID: 35385817, DOI: 10.1016/j.jpsychires.2022.03.021.Peer-Reviewed Original ResearchConceptsChronic suicidal ideationSuicidal ideationSuicidal thoughtsMood disordersNovel self-report instrumentCronbach's alphaDepression severity scoresYale-Brown ObsessiveIndex hospitalizationInpatient cohortMcDonald's omegaPast suicide attemptsSeverity scoreActivity interferenceSuicide attemptsSuicidal thinkingCompulsive ScaleSelf-report instrumentOne-factor solutionIdeationSignificant Pearson correlationScoresCohortInternal consistencyAlphaPreliminary Effectiveness of a Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality: Protocol for a Randomized Controlled Trial
Buono FD, Gleed C, Boldin M, Aviles A, Wheeler N. Preliminary Effectiveness of a Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality: Protocol for a Randomized Controlled Trial. JMIR Research Protocols 2022, 11: e30186. PMID: 35029534, PMCID: PMC8800086, DOI: 10.2196/30186.Peer-Reviewed Original ResearchINTERNATIONAL REGISTERED REPORT IDENTIFIERAlcohol use disorderQuality of lifeBlood alcohol concentrationUse disordersAlcohol use disorder populationTreatment providersPsychological distressRandomized clinical trialsLong-term treatmentTreatment motivationCost-effective treatmentControlled TrialsDisease management approachTreatment modalitiesChronic disordersAlcohol concentrationClinical trialsDropout ratePreliminary effectivenessAlcohol dependenceTimely interventionDisorder populationMonthsHigher likelihoodEffects of VHA Policy Directive 1163 on Acceptance and Employment Rates for Veterans with Substance Use Disorders Referred to VHA Vocational Rehabilitation
Sprong M, Hollender H, Pechek A, Forziat-Pytel K, Buono F. Effects of VHA Policy Directive 1163 on Acceptance and Employment Rates for Veterans with Substance Use Disorders Referred to VHA Vocational Rehabilitation. Substance Abuse Research And Treatment 2022, 16: 11782218221132397. PMID: 36452410, PMCID: PMC9703520, DOI: 10.1177/11782218221132397.Peer-Reviewed Original ResearchUse disordersSubstance/alcohol use disorderVocational rehabilitationSubstance use disordersAlcohol use disorderVocational rehabilitation programRehabilitation programCurrent studyRehabilitation servicesGreater riskVocational rehabilitation servicesVeteransProgram entryEntry dateDisordersAUDRehabilitationVocational assistanceAcceptance rateDurationRemissionConsultsFindings
2021
Innovation in the treatment of persistent pain in adults with Neurofibromatosis Type 1 (NF1): Implementation of the iCanCope mobile application
Buono FD, Lalloo C, Larkin K, Zempsky WT, Ball S, Grau LE, Pham Q, Stinson J. Innovation in the treatment of persistent pain in adults with Neurofibromatosis Type 1 (NF1): Implementation of the iCanCope mobile application. Contemporary Clinical Trials Communications 2021, 25: 100883. PMID: 35036627, PMCID: PMC8743203, DOI: 10.1016/j.conctc.2021.100883.Peer-Reviewed Original ResearchNeurofibromatosis type 1Pain symptomsNF1 populationType 1Chronic pain symptomsSelf-management treatmentPersistent painTreatment satisfactionTreatment optionsControl studySix weeksPainPsychometric evaluationContingency managementInitial effectivenessGenetic disordersThird groupSymptomsAdultsTreatmentPopulationDifferent populationsGroupParticipants' experiencesGreater reachIntensive Dialectical Behavior Treatment for Individuals With Borderline Personality Disorder With and Without Substance Use Disorders
Buono FD, Larkin K, Rowe D, Perez-Rodriguez MM, Sprong ME, Garakani A. Intensive Dialectical Behavior Treatment for Individuals With Borderline Personality Disorder With and Without Substance Use Disorders. Frontiers In Psychology 2021, 12: 629842. PMID: 34497550, PMCID: PMC8419465, DOI: 10.3389/fpsyg.2021.629842.Peer-Reviewed Original ResearchSubstance use disordersBorderline personality disorderComorbid substance use disorderUse disordersDialectical behavioral therapyTreatment programComorbid borderline personality disorderPersonality disorderDepression symptom scaleModerate depression scoresDepressive symptomsGroup 2Depression scoresGroup 1Symptom ScaleDBT treatmentSymptom overlapUnivariate general linear modelBehavioral therapyDisordersSignificant decreaseBehavior treatmentGeneral linear modelSignificant differencesPatients